Table 2 Summary of PI3KCA mutations and PTEN expression
From: PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
| Â | Â | PI3KCA | mutations | Â | Wild Type | Total |
|---|---|---|---|---|---|---|
PTEN expression | Exon | 20 | Exon | 9 | Â | Â |
(IHC score) | H1047R | T1052A | E542K | L540F | Â | Â |
negative | 3 | 0 | 0 | 0 | 15 | 18 |
weak positive | 1 | 0 | 0 | 0 | 16 | 17 |
positive | 0 | 1 | 1 | 0 | 12 | 14 |
strong positive | 0 | 0 | 0 | 1 | 7 | 8 |
Total | 4 | 1 | 1 | 1 | Â | Â |